MarginsXMarginsX
Home › Markets › Health Care › RDHL

Redhill Biopharma Ltd. (RDHL)

RDHL trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.3605
-3.87% on the day
Market cap
$3.2M
Nano cap
Revenue · 2025
$286K
-96.4% on 2024
Net income · 2025
-$429K
-150.0% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC filing XBRL, 20-F (ifrs-full:Revenue), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1553846/000110465926049055/0001104659-26-049055-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerRDHL on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryIsrael
IPO yearNot reported by the screener
SEC CIK0001553846
SEC industry codePharmaceutical Preparations
Incorporated inIsrael

Financials · 2025

LineValue
Revenue$286K
Net income-$429K
Operating income-$7.9M
Net margin-150.0%
Operating margin-2776.9%
Revenue growth-96.4%
Cash$4.0M
Total assets$25.3M
P/E (computed)Net income was not positive
P/S (computed)11.2×

Warning signs

Cash runway
4.9 months
$4.0M cash at December 31, 2025
Share count, 1 year
+294.8%
2024-12-31 to 2025-12-31 · +107814.9% over 3 years
Going-concern doubt
No
20-F filed April 27, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.
"These conditions and events indicate that a material uncertainty exists that may cast significant doubt (or raise substantial doubt as contemplated by PCAOB standards) about the Company's ability to continue as a going concern."
20-F 2026-04-27
Cash and burn$4.0M cash; operating cash flow -$2.4M a quarter.Report 2025-12-31
Shares outstanding5,092,326 (2025-12-31); 1,289,983 a year earlier; 117,971 three years earlier. 3y figure adjusted for splits (1-for-25 overall); the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures.Cover page 2025-12-31
Reverse splits, 3 years1; latest 1-for-25 on 2024-08-20Source 2024-08-20
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 4 424B5 takedowns, 4 at the marketLatest 2026-10-13
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKesselman & Kesselman C.P.A.s, Tel-Aviv, IsraelPCAOB Form AP 2026-05-18
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30
Market cap checkThe listing's market cap implies 8,887,683 shares at the 2026-11-13 price; the latest SEC cover count is 5,092,326 as of 2025-12-31. The SEC count is the older of the two, so the listing's cap is likely the current one; shares were issued since that cover page.Nasdaq screener and SEC cover page

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-12-31
$286K-$429K-$9.7M$4.0MNo debt tags$286K20-F 2026-04-27
FY 2024
2024-12-31
$8.0M-$8.3M-$9.4M$4.6MNo debt tags$8.0M20-F 2025-04-10
FY 2023
2023-12-31
$6.5M$23.9M-$35.8M$5.6MNo debt tags$6.5M20-F 2025-04-10
FY 2022
2022-12-31
$61.8M-$71.7M-$29.2M$20.0M$115.2M$61.8M20-F 2025-04-10
FY 2021
2021-12-31
$85.8M-$97.7M-$65.0M$29.5M$83.6M$85.8M20-F 2024-04-08
FY 2020
2020-12-31
$64.4M-$76.2M-$48.6M$29.3M$81.4M$64.4M20-F 2023-04-28
FY 2019
2019-12-31
$6.3M-$42.3M-$40.7M$29.0MNo debt tags$6.3M20-F 2022-03-17
FY 2018
2018-12-31
$8.4M-$38.8M-$34.5M$29.0MNo debt tags$8.4M20-F 2021-03-18

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-10-13
Latest annual report20-F2026-04-27
Latest quarterly / interim6-K2026-11-02

Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-12.4%
1 month-27.2%
3 months-37.0%
Year to date-63.6%
1 year-65.0%
From 52-week high-73.2%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
MDCXMedicus Pharma Ltd. Common Stock$1.69-13.33%$3.2M
APUSApimeds Pharmaceuticals US Inc.$2.04-8.52%$3.1M
GRIGRI Bio Inc.$1.40-18.60%$3.1M
SILOSilo Pharma Inc.$1.57-14.40%$3.4M
MBIOMustang Bio Inc.$0.3947-6.34%$3.0M
NRSNNeuroSense Therapeutics Ltd.$1.56-7.40%$3.0M
DRMADermata Therapeutics Inc.$0.5985-3.65%$3.0M
XBIOXenetic Biosciences Inc.$1.49-10.24%$3.5M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier